Last checked at 16 Jun 2017 09:57
Director's Share Dealing
London: Friday, June 16, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-
1. Dynamic Drive Limited, a person closely associated ("PCA") with Mr Simon To, Executive Director and Chairman, purchased a total of 11,158 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med ("Ordinary Share")) between June 13 and 15, 2017 at an average price of US$21.18 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the "DDT") which has been established for the benefit of Mr To's family members, of which Mr To is the settlor;
2. Wencheng Capital Limited ("WCL"), a PCA with Mr To, purchased a total of 25,669 ADSs between June 13 and 15, 2017 at an average price of US$21.15 per ADS. WCL is controlled by the trustee of Wencheng Trust ("WT") which has been established for the benefit of Mr To's family member, of which Mr To is the settlor;
3. Mr To transferred a total of 70,000 ADSs from an account in his own name to WCL on June 14, 2017; and
4. Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 25,403 ADSs on June 14 and 15, 2017 at an average price of US$21.17 per ADS.
Following the above purchase of a total of 36,827 ADSs and transfer of 70,000 ADSs, Mr To is interested in 106,827 ADSs (in DDT and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.38% of the current issued share capital of Chi-Med.
Following the above purchase, Ms Shih is interested in 76,144 ADSs and 60,000 Ordinary Shares, representing approximately 0.16% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) |
Name |
Dynamic Drive Limited
|
2 | Reason for the notification | |
a) |
Position/status |
Person closely associated with Mr Simon To, Executive Director and Chairman. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor.
|
b) |
Initial notification/Amendment
|
Initial notification
|
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||
a) |
Description of the financial instrument, type of instrument Identification code
|
ADS each representing one half of one Ordinary Share of US$1.00
ADS ISIN: US44842L1035
| ||||||||||
b) |
Nature of the transaction
| Acquisition of 11,158 ADSs in the name of Dynamic Drive Limited which holds the ADSs for a family trust (Dynamic Drive Trust) of which Mr To is the settlor between June 13 and 15, 2017 at an average price of US$21.18 per ADS | ||||||||||
c) |
Price(s) and volume(s) |
| ||||||||||
d) |
Aggregated information
|
Aggregated volume: 11,158 Price information: US$21.18 | ||||||||||
e) |
Date of the transaction |
2017-06-13 - acquisition of 6,780 ADSs 2017-06-14 - acquisition of 500 ADSs 2017-06-15 - acquisition of 3,878 ADSs
| ||||||||||
f) |
Place of the transaction |
Nasdaq Stock Market
| ||||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||||
a) |
Name |
Wencheng Capital Limited
| ||||||||||
2 | Reason for the notification | |||||||||||
a) |
Position/status |
Person closely associated with Mr Simon To, Executive Director and Chairman. Wencheng Capital Limited is controlled by the trustee of Wencheng Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor.
| ||||||||||
b) |
Initial notification/Amendment
|
Initial notification
| ||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||
a) |
Description of the financial instrument, type of instrument Identification code
|
ADS each representing one half of one Ordinary Share of US$1.00
ADS ISIN: US44842L1035
| ||||||||||
b) |
Nature of the transaction
| Acquisition of 25,669 ADSs in the name of Wencheng Capital Limited which holds the ADSs for a family trust (Wencheng Trust) of which Mr To is the settlor between June 13 and 15, 2017 at an average price of US$21.15 per ADS | ||||||||||
c) |
Price(s) and volume(s) |
| ||||||||||
d) |
Aggregated information
|
Aggregated volume: 25,669 Price information: US$21.15 | ||||||||||
e) |
Date of the transaction |
2017-06-13 - acquisition of 16,958 ADSs 2017-06-14 - acquisition of 1,300 ADSs 2017-06-15 - acquisition of 7,411 ADSs
| ||||||||||
f) |
Place of the transaction |
Nasdaq Stock Market
| ||||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||
a) |
Name |
Mr Simon To
| |||||||
2 | Reason for the notification | ||||||||
a) |
Position/status |
Executive Director and Chairman
| |||||||
b) |
Initial notification/Amendment
|
Initial notification
| |||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||
a) |
Name
|
Hutchison China MediTech Limited | |||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | |||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
a) |
Description of the financial instrument, type of instrument Identification code
|
ADS each representing one half of one Ordinary Share of US$1.00
ADS ISIN: US44842L1035
| |||||||
b) |
Nature of the transaction
|
Disposal of 70,000 ADSs from Mr Simon To to Wencheng Capital Limited which holds the ADSs for a trust (Wencheng Trust), established for the benefit of Mr To's family members, of which Mr To is the settlor on June 14, 2017 | |||||||
c) |
Price(s) and volume(s) |
| |||||||
d) |
Aggregated information
|
N/A | |||||||
e) |
Date of the transaction |
2017-06-14
| |||||||
f) |
Place of the transaction |
Outside a trading venue
| |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) |
Name |
Wencheng Capital Limited
| ||||||
2 | Reason for the notification | |||||||
a) |
Position/status |
Person closely associated with Mr Simon To, Executive Director and Chairman. Wencheng Capital Limited is controlled by the trustee of Wencheng Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor.
| ||||||
b) |
Initial notification/Amendment
|
Initial notification
| ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) |
Description of the financial instrument, type of instrument Identification code
|
ADS each representing one half of one Ordinary Share of US$1.00
ADS ISIN: US44842L1035
| ||||||
b) |
Nature of the transaction
|
Acquisition of 70,000 ADSs in the name of Wencheng Capital Limited which holds the ADSs for a family trust (Wencheng Trust) of which Mr To is the settlor on June 14, 2017 | ||||||
c) |
Price(s) and volume(s) |
| ||||||
d) |
Aggregated information
|
N/A | ||||||
e) |
Date of the transaction |
2017-06-14
| ||||||
f) |
Place of the transaction |
Outside a trading venue
| ||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||||
a) |
Name |
Ms Edith Shih
| ||||||||||
2 | Reason for the notification | |||||||||||
a) |
Position/status |
Non-executive Director and Company Secretary
| ||||||||||
b) |
Initial notification/Amendment
|
Initial notification
| ||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||
a) |
Description of the financial instrument, type of instrument Identification code
|
ADS each representing one half of one Ordinary Share of US$1.00
ADS ISIN: US44842L1035
| ||||||||||
b) |
Nature of the transaction
|
Acquisition of 25,403 ADSs on June 14 and 15, 2017 at an average price of US$21.17 per ADS | ||||||||||
c) |
Price(s) and volume(s) |
| ||||||||||
d) |
Aggregated information
|
Aggregated volume: 25,403 Price information: US$21.17 | ||||||||||
e) |
Date of the transaction |
2017-06-14 - Acquisition of 24,445 ADSs 2017-06-15 - Acquisition of 958 ADSs
| ||||||||||
f) |
Place of the transaction |
Nasdaq Stock Market
| ||||||||||
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries | ||
Christian Hogg, CEO | +852 2121 8200 | |
U.K. & International Media Enquiries | ||
Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) | anthony.carlisle@cdrconsultancy.co.uk |
U.S. Based Media Enquiries | ||
Brad Miles, BMC Communications | +1 (917) 570 7340 (Mobile) | bmiles@bmccommunications.com |
Susan Duffy, BMC Communications | +1 (917) 499 8887 (Mobile) | sduffy@bmccommunications.com |
Investor Relations | ||
Matt Beck, The Trout Group | +1 (917) 415 1750 (Mobile) | mbeck@troutgroup.com |
David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) | david.dible@citigatedr.co.uk |
Panmure Gordon (UK) Limited | ||
Richard Gray / Andrew Potts | +44 (20) 7886 2500 |